AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10511389 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (after exclusion of a trial with extreme results)
Number of subjects: 2609
Study 7772429 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.22% halothane
Number of subjects: 12
Study 7772429 — intervention group
Group type: COMPARATOR
Intervention: Control (no halothane)
Number of subjects: 12
Study 1828408 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaprazole (450 mg bid)
Number of subjects: 50
Study 1828408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulglicotide (200 mg tid)
Number of subjects: 50
Study 7014284 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg i.m. domperidone
Number of subjects: 42
Study 7014284 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg t.i.d. domperidone
Number of subjects: 42
Study 7014284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31631377 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 1829
Study 28389389 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin nasal spray
Number of subjects: 33
Study 28389389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 26010860 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20mg/day for 6 weeks, with dose escalation up to 50mg/day for non-responders
Number of subjects: 70
Study 26010860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fatty fish intake
Number of subjects: 70
Study 26010860 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial low FA-chain length, FA-peroxidation, and EPA in early responders
Number of subjects: 70
Study 26010860 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol and FA measures repeated after 6 and 12 weeks
Number of subjects: 70
Study 23229087 — intervention group
Group type: EXPERIMENTAL
Intervention: Facing Forward booklet
Number of subjects: 340
Study 23229087 — intervention group
Group type: COMPARATOR
Intervention: Attention control booklet about the NCI's Cancer Information Service
Number of subjects: 340
Study 21300339 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot leuprolide, 11.25 mg IM every 12 weeks with hormonal add-back using norethindrone acetate 5 mg orally, daily
Number of subjects: 47
Study 21300339 — intervention group
Group type: COMPARATOR
Intervention: Generic monophasic oral contraceptive (1 mg norethindrone + 35 mg ethinyl estradiol) given daily
Number of subjects: 47
Study 19485822 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTG with a retained epithelial collar + CAF (SCTGE; n = 10)
Number of subjects: 20
Study 19485822 — intervention group
Group type: COMPARATOR
Intervention: SCTG without an epithelial collar + CAF (SCTGN; n = 10)
Number of subjects: 20
Study 19485822 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTGE
Number of subjects: 20
Study 19485822 — intervention group
Group type: COMPARATOR
Intervention: SCTGN
Number of subjects: 20
Study 16563078 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline Personality Disorder (BPD) group
Number of subjects: 41
Study 16563078 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 16563078 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic item recognition memory
Number of subjects: 41
Study 15503074 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention program (six modules in five weekly group sessions)
Number of subjects: 22
Study 15503074 — intervention group
Group type: COMPARATOR
Intervention: Comparison group without intervention
Number of subjects: 22
Study 11416677 — intervention group
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil 16 mg once daily, increased to 32 mg after 2 weeks
Number of subjects: 654
Study 11416677 — intervention group
Group type: COMPARATOR
Intervention: losartan 50 mg once daily, increased to 100 mg after 2 weeks
Number of subjects: 654
Study 11416677 — intervention group
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil
Number of subjects: 654
Study 11416677 — intervention group
Group type: COMPARATOR
Intervention: losartan
Number of subjects: 654
Study 9293650 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml of 0.125% bupivacaine (with 1/200,000 epinephrine)
Number of subjects: 60
Study 9293650 — intervention group
Group type: COMPARATOR
Intervention: 30 ml of isotonic saline (with 1/200,000 epinephrine)
Number of subjects: 60
Study 8447520 — intervention group
Group type: EXPERIMENTAL
Intervention: Low clearing doses of ivermectin followed by 200-400 micrograms/kg of ivermectin
Number of subjects: 59
Study 8447520 — intervention group
Group type: EXPERIMENTAL
Intervention: 220 micrograms/kg of ivermectin
Number of subjects: 59
Study 8447520 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 or 7 mg/kg of DEC
Number of subjects: 59
Study 8447520 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearing dose of ivermectin followed by 6 mg/kg of DEC
Number of subjects: 59
Study 8447520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 3768248 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline preparation with ethylenediamine
Number of subjects: 6
Study 3768248 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline preparation with sodium glycinate
Number of subjects: 6
Study 29696963 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (on the basis of aspirin)
Number of subjects: 92
Study 29696963 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (control group)
Number of subjects: 92
Study 26796240 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 19
Study 26796240 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Whole-body vibration (EX + WBV)
Number of subjects: 19
Study 24178976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cockcroft and Gault estimated GFR tertiles
Number of subjects: 768
Study 24178976 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of Diet in Renal Disease estimated GFR tertiles
Number of subjects: 768
Study 24178976 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease‐Epidemiology Collaboration estimated GFR tertiles
Number of subjects: 768
Study 23365129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet and low-dose vitamin D sterols (Cin-D)
Number of subjects: 304
Study 23365129 — intervention group
Group type: COMPARATOR
Intervention: Larger, varying doses of calcitriol or other vitamin D analogs (Flex-D)
Number of subjects: 304
Study 20601929 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited partner therapy (EPT)
Number of subjects: 0
Study 20601929 — intervention group
Group type: COMPARATOR
Intervention: Standard partner referral (SPR)
Number of subjects: 0
Study 18664833 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated polyp size measurement tool in computed tomographic colonography
Number of subjects: 0
Study 18664833 — intervention group
Group type: COMPARATOR
Intervention: Manual and endoscopic measurements
Number of subjects: 0
Study 16422889 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone patch (5 mg/day applied at 2200 h)
Number of subjects: 28
Study 16422889 — intervention group
Group type: COMPARATOR
Intervention: Testosterone gel (5 g/day applied at 0800 h)
Number of subjects: 28
Study 12835492 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg/d) for 14 weeks followed by copper supplementation (3 mg/d) for 8 weeks
Number of subjects: 38
Study 12835492 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplements for the full duration of the trial
Number of subjects: 38
Study 10805844 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute ethanol
Number of subjects: 157
Study 10805844 — intervention group
Group type: COMPARATOR
Intervention: 5% ethanolamine oleate
Number of subjects: 157
Study 8873633 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline therapy
Number of subjects: 612
Study 8873633 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 612
Study 1387041 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terfenadine (120 mg)
Number of subjects: 8
Study 1387041 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal ipratropium bromide (80 micrograms)
Number of subjects: 8
Study 1387041 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terfenadine (120 mg) and nasal ipratropium bromide (80 micrograms)
Number of subjects: 8
Study 1387041 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 8
Study 6437102 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg levonorgestrel per coitus
Number of subjects: 104
Study 6437102 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg levonorgestrel per coitus
Number of subjects: 104
Study 6437102 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of levonorgestrel
Number of subjects: 104
Study 6437102 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel for postcoital contraception
Number of subjects: 104
Study 30266256 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic life events
Number of subjects: 24809
Study 30266256 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial stress
Number of subjects: 24809
Study 30266256 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood stress
Number of subjects: 24809
Study 30266256 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed AF prevalence
Number of subjects: 24809
Study 27445627 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 12982
Study 27445627 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain severity
Number of subjects: 12982
Study 24670520 — intervention group
Group type: EXPERIMENTAL
Intervention: rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF)
Number of subjects: 476
Study 24670520 — intervention group
Group type: COMPARATOR
Intervention: protease inhibitor+RTV+two NRTIs
Number of subjects: 476
Study 23158423 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (35 ml contrast medium)
Number of subjects: 120
Study 23158423 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (40 ml contrast medium)
Number of subjects: 120
Study 23158423 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (45 ml contrast medium)
Number of subjects: 120
Study 23158423 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (50 ml contrast medium)
Number of subjects: 120
Study 19022318 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intradermal injection (3 microg hemagglutinin per strain) using MicronJet (ID1 group)
Number of subjects: 180
Study 19022318 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose intradermal injection (6 microg hemagglutinin per strain) using MicronJet (ID2 group)
Number of subjects: 180
Study 19022318 — intervention group
Group type: COMPARATOR
Intervention: Full-dose standard flu shot (15 microg hemagglutinin per strain) delivered intramuscularly (IM group)
Number of subjects: 180
Study 17509210 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol
Number of subjects: 27
Study 17509210 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist protocol
Number of subjects: 27
Study 16032525 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-cohort study design
Number of subjects: 0
Study 16032525 — intervention group
Group type: COMPARATOR
Intervention: Full cohort study
Number of subjects: 0
Study 11927418 — intervention group
Group type: EXPERIMENTAL
Intervention: Conductive keratoplasty (CK)
Number of subjects: 54
Study 9813675 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and Herbert screw fixation
Number of subjects: 12
Study 9813675 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and Kirschner wire fixation
Number of subjects: 12
Study 8088392 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic electromyostimulation (CEMS)
Number of subjects: 0
Study 8088392 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous nerve stimulation (TENS) placebo
Number of subjects: 0
Study 2574193 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (N = 21; mean diazepam dose equivalents, 15 mg/day; range, 5‐40)
Number of subjects: 63
Study 2574193 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 19)
Number of subjects: 63
Study 30583913 — intervention group
Group type: EXPERIMENTAL
Intervention: Meducation® eye drop technique video
Number of subjects: 92
Study 30583913 — intervention group
Group type: COMPARATOR
Intervention: Nutrition video
Number of subjects: 92
Study 28665371 — intervention group
Group type: EXPERIMENTAL
Intervention: mexidol: 500 mg/day IV infusion for 10 days, followed by 125 mg tid (375 mg/day) PO for 8 weeks
Number of subjects: 151
Study 28665371 — intervention group
Group type: EXPERIMENTAL
Intervention: mexidol
Number of subjects: 151
Study 28665371 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 151
Study 24934438 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 12
Study 24934438 — intervention group
Group type: COMPARATOR
Intervention: Labour pain
Number of subjects: 12
Study 23457387 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Methotrexate (MTX), n = 37
Number of subjects: 152
Study 23457387 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (combined 50 mg + MTX or 100 mg ± MTX), n = 115
Number of subjects: 152
Study 21930598 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior endurance exercise (∼50 min)
Number of subjects: 10
Study 21930598 — intervention group
Group type: COMPARATOR
Intervention: Control (no prior exercise)
Number of subjects: 10
Study 19197778 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking Consequences Questionnaire-Adult (SCQ-A)
Number of subjects: 751
Study 16786407 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim's emotional response severity (severe)
Number of subjects: 0
Study 16786407 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim's emotional response severity (mild)
Number of subjects: 0
Study 16786407 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportionality norm (matching emotional response to crime seriousness)
Number of subjects: 0
Study 16786407 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender of the victim
Number of subjects: 0
Study 15173128 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium intake (sodium restriction)
Number of subjects: 12
Study 12117291 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin rinse at 2,000 IU/L
Number of subjects: 11
Study 12117291 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin rinse at 10,000 IU/L
Number of subjects: 11
Study 12117291 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline rinse
Number of subjects: 11
Study 12117291 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (comparison group)
Number of subjects: 11
Study 9647354 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin mini-erosion sampling technique
Number of subjects: 13
Study 8077904 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal paracervical block
Number of subjects: 77
Study 8077904 — intervention group
Group type: COMPARATOR
Intervention: Intramucosal block
Number of subjects: 77
Study 8077904 — intervention group
Group type: EXPERIMENTAL
Intervention: Both blocks
Number of subjects: 77
Study 2555894 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygynax
Number of subjects: 115
Study 2555894 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study 1114210 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive preoperative interview (long and relatively informative with maximal rapport)
Number of subjects: 40
Study 1114210 — intervention group
Group type: COMPARATOR
Intervention: Cursory preoperative interview (brief and minimally informative)
Number of subjects: 40
Study 30898822 — intervention group
Group type: COMPARATOR
Intervention: Belimumab SC 200 mg/week for 52 weeks plus placebo at weeks 4 and 6
Number of subjects: 200
Study 30898822 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab SC 200 mg/week for 52 weeks plus rituximab 1000 mg at weeks 4 and 6
Number of subjects: 200
Study 30898822 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab SC 200 mg/week plus standard of care for 104 weeks
Number of subjects: 200
Study 28319456 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervarix®
Number of subjects: 198
Study 28319456 — intervention group
Group type: COMPARATOR
Intervention: Gardasil®
Number of subjects: 198
Study 28319456 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 198
Study 25477424 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg 6R‐BH4 twice daily + 1 mg folic acid once daily
Number of subjects: 36
Study 25477424 — intervention group
Group type: COMPARATOR
Intervention: Placebo + folic acid
Number of subjects: 36
Study 24147622 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (20 mg/kg/day, titrated to 5-10 mg/kg/day based on serum ferritin trends)
Number of subjects: 117
Study 24147622 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (mean actual dose 33.6 mg/kg/day in 1-year extension)
Number of subjects: 117
Study 24147622 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 117
Study 24147622 — intervention group
Group type: COMPARATOR
Intervention: Deferasirox (compared to non-Chinese patients)
Number of subjects: 117
Study 21879641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Number of subjects: 22
Study 21879641 — intervention group
Group type: COMPARATOR
Intervention: Individual cognitive-behavioral therapy
Number of subjects: 22
Study 19517675 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anaesthesia (group B, n=27, 0.5% hyperbaric bupivacaine, 1.2 mL + 0.1 mL per every 10 cm over 170 cm height)
Number of subjects: 54
Study 19517675 — intervention group
Group type: COMPARATOR
Intervention: Bilateral spinal anaesthesia (group K, n=27, 0.5% bupivacaine 2.4 mL + 0.2 mL per every 10 cm over 170 cm height)
Number of subjects: 54
Study 16997310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 81
Study 16997310 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 81
Study 15564907 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional exercises matching their preferred direction (DP)
Number of subjects: 312
Study 15564907 — intervention group
Group type: COMPARATOR
Intervention: Exercises directionally opposite their DP
Number of subjects: 312
Study 15564907 — intervention group
Group type: COMPARATOR
Intervention: Nondirectional exercises
Number of subjects: 312
Study 11287776 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine 50 mg/day
Number of subjects: 36
Study 11287776 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine 100 mg/day
Number of subjects: 36
Study 11287776 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy
Number of subjects: 36
Study 9148879 — intervention group
Group type: EXPERIMENTAL
Intervention: Involuntary outpatient commitment (OPC)
Number of subjects: 0
Study 9148879 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7999470 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography restricted to women with risk factors for breast cancer
Number of subjects: 0
Study 7999470 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual screening prescriptions based on risk
Number of subjects: 0
Study 7999470 — intervention group
Group type: COMPARATOR
Intervention: General screening for all women younger than 50
Number of subjects: 0
Study 31906801 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Training (BT) conducted over five weeks
Number of subjects: 72
Study 31906801 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) receiving regular physical education lessons
Number of subjects: 72
Study 30085175 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 240
Study 30085175 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 240
Study 27564856 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical decompression and fusion (ACDF) plus physiotherapy
Number of subjects: 59
Study 27564856 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 59
Study 26523993 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg daily for 104 weeks
Number of subjects: 458
Study 26523993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study 24131167 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch + nicotine nasal spray
Number of subjects: 22
Study 24131167 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch + placebo nasal spray
Number of subjects: 22
Study 21112774 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT) with cisplatin (100mg/m(2) for three cycles) plus adjuvant cisplatin (80 mg/m(2)) and fluorouracil (1000 mg/m(2)/day for 4 days for three cycles)
Number of subjects: 441
Study 21112774 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 441
Study 21112774 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 441
Study 21112774 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin during concurrent phase
Number of subjects: 441
Study 21112774 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil during adjuvant phase
Number of subjects: 441
Study 21112774 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cycles of cisplatin
Number of subjects: 441
Study 18438106 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal food at will from the first day after surgery
Number of subjects: 453
Study 18438106 — intervention group
Group type: COMPARATOR
Intervention: Nil‐by‐mouth and enteral tube feeding (ETF group)
Number of subjects: 453
Study 16180033 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-ECD/123I-FP-CIT SPECT in IPD patients
Number of subjects: 19
Study 16180033 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-ECD/123I-FP-CIT SPECT in MSA patients
Number of subjects: 19
Study 16180033 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 19
Study 12657406 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (1,000,000 KIU loading dose, followed by an infusion of 250,000 KIU/hr)
Number of subjects: 63